What Analysts Are Saying About Teva Pharmaceutical After Earnings

Teva Pharmaceuticals Industries Ltd. swung to a loss in its latest quarter on an acquisition write-down as its interim chief executive contends with a deal-driven debt load. Bourgeon Capital Management LLC increased its position in Teva Pharmaceutical Industries Limited by 21.4% in the second quarter. Teva Pharmaceutical Industries Limited had a return on equity of 16.75% and a net margin of 8.81%. Sanford C. Bernstein set a $42.00 price target on Teva Pharmaceutical Industries Limited and gave the company a buy rating in a research report on Tuesday, February 7th.

The Israel-based company reiterates its guidance for 2017 full year non-GAAP, including $4.90 - 5.30 non-GAAP EPS and $23.8 - 24.5 billion revenue.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 33.94 on Tuesday.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hudock Capital Group LLC increased its position in Teva Pharmaceutical Industries Limited by 37.6% in the second quarter.

TEVA was trading -44.55% below its 52-week high and 0.91% above its 52-week low. Deutsche Bank AG lowered their target price on Teva Pharmaceutical Industries Limited from $68.00 to $54.00 and set a buy rating for the company in a research note on Wednesday, November 16th. 23 Analysts think that the Price Target for Teva Pharmaceutical Industries Limited (NYSE:TEVA) might hit $42.65, however, the High Price Target and Low price Target are $80 and $31, respectively.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has a market capitalization of 34.51 Billion.

Revenue grew 33% to $6.49 billion. The stock stands -8.83% below the average-price of 50 days and -4.25% compared with the SMA 20. The company's quarterly performance represents an optimistic momentum of 17.42 percent, with a surge of 11.03 percent in the stock price over the last one month. Finally, Oppenheimer Holdings, Inc. restated an "outperform" rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, December 7th. If you are viewing this article on another publication, it was stolen and republished in violation of U.S. and global copyright & trademark legislation.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is now showing its ROA (Return on Assets) of 2.4%.

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 20th. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-rating-reiterated-by-rbc-capital-markets/431511.html. Shareholders of record on Thursday, March 2nd will be given a dividend of $0.34 per share.

The stock now has its Annual Dividend of $1.36 and an annual Dividend Yield of 4 Percent. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is now 67.44%.

"Teva Pharmaceutical Industries Limited (TEVA) Shares Sold by Loudon Investment Management LLC" was originally posted by Community Financial News and is the property of of Community Financial News.

A sequence of expensive acquisitions together with the delayed launches of drug have sent the shares of Teva plunging and resulted in calls for structural and management changes, including a potential division into separate branded and generic medicine units.

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.

Global sales of Copaxone rose 6 percent in the quarter to $1.0 billion.